0001493152-22-017665.txt : 20220624
0001493152-22-017665.hdr.sgml : 20220624
20220624081847
ACCESSION NUMBER: 0001493152-22-017665
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220622
FILED AS OF DATE: 20220624
DATE AS OF CHANGE: 20220624
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Daugherty Frank Joseph
CENTRAL INDEX KEY: 0001806875
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39555
FILM NUMBER: 221037015
MAIL ADDRESS:
STREET 1: 2311 SPARTAN TRAIL
CITY: SUGAR LAND
STATE: TX
ZIP: 77479
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Greenwich LifeSciences, Inc.
CENTRAL INDEX KEY: 0001799788
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205473709
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3992 BLUEBONNET DR, BUILDING 14
CITY: STAFFORD
STATE: TX
ZIP: 77477
BUSINESS PHONE: 203-434-3290
MAIL ADDRESS:
STREET 1: 3992 BLUEBONNET DR, BUILDING 14
CITY: STAFFORD
STATE: TX
ZIP: 77477
4
1
ownership.xml
X0306
4
2022-06-22
0
0001799788
Greenwich LifeSciences, Inc.
GLSI
0001806875
Daugherty Frank Joseph
C/O GREENWICH LIFESCIENCES, INC.
3992 BLUEBONNET DR., BUILDING 14
STAFFORD
TX
77477
1
1
0
0
Chief Medical Officer
Stock Options
7.63
2022-06-22
4
A
0
104890
0
A
2032-06-22
Common Stock
104890
104890
D
The options vest over time and pursuant to milestones. 2,185 of the options vest each month for 48 months contingent on the Company meeting certain performance milestones. The Reporting Person is eligible to exercise (i) 25% after the first site is activated for the Phase 3 clinical trial, (ii) 50% after completion of interim analysis of the Phase 3 clinical trial and (iii) 25% upon filing of Biologic License Application with the US Food and Drug Administration.
/s/ Frank Daugherty
2022-06-24